Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, has operationalized the first phase of its biologics manufacturing facility in Bangalore, India through its 100% subsidiary, Aragen Biologics Pvt Ltd.
Aragen Life Sciences to invest Rs 2,000 cr for expansion of facility in Hyderabad
Aragen Life Sciences is launching a new $30 million biologics manufacturing site in Bangalore due to growing demand, the India-based drug manufacturer said Monday.
HYDERABAD, India, May 30, 2023 /PRNewswire/ -- Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration. As part of the collaboration, Aragen will deploy its proven experimental discovery platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration.
Aragen is set to open their new manufacturing facility at their Mallapur campus in Hyderabad, India in January 2023, enhancing the company’s ability to provide scaled manufacturing solutions and clinical supplies to their customers.
Aragen, a leading contract research development and manufacturing organization (CRDMO), has announced that it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad by January 2023. The 12,000 square feet new facility will strengthen the company’s ability to deliver clinical supplies to customers through its integrated drug substance and drug product development and manufacturing.
Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO), today announced that it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India by January 2023. The 12,000 square feet new facility will strengthen the company’s ability to deliver clinical supplies to customers through its integrated drug substance and drug product development and manufacturing.
Hyderabad: Aragen Life Sciences Private Limited announced that it has entered into an agreement with UK-based company, NeoVac, for manufacturing a lipid product that will support the development of lipid nanoparticles (LNP) for use in developing RNA vaccines for various diseases. Aragen has been working with NeoVac since early December 2021 on process research development (PRD) for the lipid product.
Aragen Life Sciences Private Limited (Aragen), a global research, development, and manufacturing services provider, announced that it has entered into an agreement with a UK-based company, NeoVac, for manufacturing a lipid product that will support the development of lipid nanoparticles (LNP) for use in developing RNA vaccines for various diseases.
The CRO in question, Synchron Research Services, isn’t the first to come under the microscope for data failings. The FDA and EMA have raised similar questions in the past regarding data findings from several India-based CROs, including Semler Research and GVK Biosciences. In the case of Semler, as in the case of Synchron, regulators are requiring the drug sponsors to repeat their bioequivalence/bioavailability studies at an acceptable alternate study site.